Gendeleka G F
Lik Sprava. 1996 Mar-Apr(3-4):100-3.
Peroral sugar-reducing agents have come to be routinely used in the treatment of type-II diabetes mellitus. The chief representatives of this group of drug preparations are derivatives of sulfonylurea. However, following a certain period of time of effective utilization of sulfanilamides, there develops secondary sulfanilamide resistance. An analysis has been performed of causes of low effectiveness of sulfonylurea derivatives in the treatment of type-II diabetes mellitus. Errors in the policy of treating diabetes mellitus with the above drug preparations are analysed as are causes of secondary insulin dependence.
口服降糖药已被常规用于治疗II型糖尿病。这类药物制剂的主要代表是磺脲类衍生物。然而，在磺胺类药物有效使用一段时间后，会产生继发性磺胺类耐药性。已对磺脲类衍生物治疗II型糖尿病疗效不佳的原因进行了分析。分析了使用上述药物制剂治疗糖尿病策略中的错误以及继发性胰岛素依赖的原因。
